SEQIRUS for SEQIRUS
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
FY2024 and FY2025 Appropriations and supplemental appropriations, policies related to pandemic preparedness and public health; FY2024 and FY2025 President's Budget proposals, policies related to pandemic preparedness and public health; seasonal and pandemic influenza preparedness; HR 5846/S 3219, Pandemic and All-Hazards Preparedness Reauthorization; Implementation of the National Influenzas Vaccine Modernization Strategy; FY2025 NDAA
Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE FARQUHARSON | — |
Health Issues HCR
FY2024 and FY2025 Appropriations and supplemental appropriations, policies related to pandemic preparedness and public health; FY2024 and FY2025 President's Budget proposals, policies related to pandemic preparedness and public health; seasonal and pandemic influenza preparedness; HR 5846/S 3219, Pandemic and All-Hazards Preparedness Reauthorization; implementation of the National Influenzas Vaccine Modernization Strategy; FY2025 NDAA; S. 3558, A bill to prohibit contracting with certain biotechnology providers and for other purposes
Foreign entity interest: CSL Limited, identified on Registration (LD-1), is the parent company of Seqirus and benefits from the financial success thereof.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTINE FARQUHARSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.